Claudin-1和HBME-1在甲狀腺乳頭狀癌組織中的表達(dá)及臨床意

劉玉蘭，胡婕，陳金蓉，陳仕高Claudin-1和HBME-1在甲狀腺乳頭狀癌組織中的表達(dá)及臨床意義劉玉蘭，胡婕，陳金蓉，陳仕高Claudin-1和HBME-1在甲狀腺乳頭狀癌組織中的表達(dá)及臨床意義-99-1材料與方法1.1一般資料1.2方法1.3統(tǒng)計(jì)學(xué)方法2結(jié)果2.1病灶組織中Claudin-1和HBME-1的表達(dá)2.2Claudin-1和HBME-1的表達(dá)情況與甲狀腺乳頭狀癌一般特征的單因素分析2.3Claudin-1和HBME-1的表達(dá)相關(guān)性分析表1兩組Claudin-1免疫組化結(jié)果比較組別n陽(yáng)性陰性陽(yáng)性率觀(guān)察組99702970.7%對(duì)照組996936.5%表2兩組HBME-1免疫組化結(jié)果比較組別n陽(yáng)性陰性陽(yáng)性率觀(guān)察組99762376.8%對(duì)照組995945.3%ABCABC圖APTC的HE染色結(jié)果HE40×圖BClaudin-1陽(yáng)性染色I(xiàn)HC40×圖CHBME-1陽(yáng)性染色I(xiàn)HC40×表3Claudin-1及HBME-1表達(dá)情況與甲狀腺乳頭狀癌影響因素的單因素分析［ｎ（％）］影響因素nClaudin-1陽(yáng)性c2PHBME-1陽(yáng)性c2P性別男2314(0.607)1.40.23713(0.565)6.8860.009女7656(0.737)63(0.829)年齡（歲）>503018(0.600)2.3830.12322(0.733)0.2850.594≤506952(0.754)54(0.783)病灶大?。╟m）>13026(0.867)5.2930.02129(0.967)9.5560.002≤16944(0.638)47(0.681)淋巴結(jié)轉(zhuǎn)移有43(0.750)0.0370.8473(0.750)0.0070.932無(wú)9567(0.705)73(0.768)腫瘤數(shù)量（個(gè)）16645(0.682)0.610.43551(0.773)0.0280.866>13325(0.758)25(0.758)被膜侵犯是5949(0.831)10.7420.00154(0.915)17.832<0.001否4021(0.525)22(0.550)表4PTC組織中Claudin-1及HBME-1表達(dá)的相關(guān)性Claudin-1HBME-1r值P值陽(yáng)性陰性陽(yáng)性47230.2240.026陰性2903討論參考文獻(xiàn)MaiaFF,Zantut-WittmannDE.Thyroidnodulemanagement:clinical,ultrasoundandcytopathologicalparametersforpredictingmalignancy[J].Clinics,2012,67(8):945-954.ZhuX,YaoJ,TianW.Microarraytechnologytoinvestigategenesassociatedwithpapillarythyroidcarcinoma[J].MolMedRep,2015,11(5):3729-3733.RaposoL,MoraisS,OliveiraMJ,etal.TrendsinthyroidcancerincidenceandmortalityinPortugal[J].EurJCancerPrev,2016,26(2):135-143.BhatAA,SyedN,TherachiyilL,etal.Claudin-1,adouble-edgedswordincancer[J].IntJMolSci,2020,21,569.DuYL,LiangY,CaoY,etal.LncRNAXISTPromotesmigrationandinvasionofpapillarythyroidcancercellbymodulatingmiR-101-3p/CLDN1axis[J].BiochemGenet,2021,59(2):437-452.HasimotoY,OkadaY,ShirakuraK,etal.Anti-claudinantibodiesasaconceptfordevelopmentofclaudin-directeddrugs[J].PharmacolExpTher,2019,368(2):179-186.郭欣，吳志宇等.Claudin-1蛋白在甲狀腺癌中的表達(dá)及調(diào)